Neutralizing antibodies (nAb) to SARS-CoV-2 induced by vaccines and/or natural infection decline over time, and there is insufficient knowledge of the cellular immune response induced by different vaccine platforms. This study compared humoral and cellular immune responses in individuals vaccinated with different SARS-CoV-2 vaccines. Participants (>18 years old) received two doses of CoronaVac (n=7), ChAdOx1 (n=8), or BNT162b2 (n=21) up to 6 months prior. Percent inhibition (PI) of neutralizing antibodies (nAb) was assessed using the ECO F Covid nAb kit. Interferon-gamma-producing T cells in response to spike protein peptides mega pools (MP) from the original SARS-CoV-2 sequence, as well as the Gamma and Delta variants, were quantified using ELISPOT. Results were expressed as cells forming spots (CFS)/106 cells. The mean age in the ChAdOx1 group (37 years) was higher than in the Coronavac (19 years) and BNT162b2 groups (22 years) (p=0.001 and 0.03, respectively). The time between vaccination and enrollment was 6 months for ChAdOx1, 5 months for CoronaVac, and 4 months for BNT162b2 (p=0.01). nAb was detected in 57% of CoronaVac participants and in all ChAdOx1 and BNT162b2 participants (p<0.0001). The median PI in the CoronaVac group (59%, 0-99%) was significantly lower than in the ChAdOx1 (99%, 90-100%; p=0.03) and BNT162b2 (99%, 42-100%; p=0.01) groups. Cellular immune response rates to the original sequence, Gamma and Delta variants were similar between groups (Wuhan 􀂱 CoronaVac: 59 CFS/106 cells; ChAdOx1: 223 CFS/106 cells; BNT162b2: 582 CFS/106 cells. Gamma variant 􀂱 CoronaVac: 199 CFS/106 cells; ChAdOx1: 163 CFS/106 cells; BNT162b2: 722 CFS/106 cells. Delta variant 􀂱 CoronaVac: 83 CFS/106 cells; ChAdOx1: 278 CFS/106 cells; BNT162b2: 710 CFS/106 cells). In conclusion, nAb PI was higher in individuals vaccinated with BNT162b2 and ChAdOx1 and cellular immune response elicited by vaccines against SAR-CoV-2 was similar.